Oxygen Consumption in Adolescent Idiopathic Scoliosis
Effect of Conservative Treatment on Pulmonary Functions, Gait Oxygen Consumption Balance and Lower Limb Load Distribution in Adolescents With Idiopathic Scoliosis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Famagusta
-
Mersin, Famagusta, Turkey, 99628
- Eastern Mediterranean University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Cobb angle between 20-45 degree,
- Prescribed a rigid spinal brace by doctor
Exclusion Criteria:
- Having leg length discrepancy more than 1 centimeter
- Having a lung disease
- Having another orthopedic or neurologic disorder
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Adolescent Idiopathic Scoliosis
Subjects with AIS who are beginning to the conservative treatment.
|
Custom made rigid thermoplastic brace with 23 hours daily wearing time.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Gait Oxygen Consumption
Time Frame: Assessment will be done at the end of first month of conservative treatment.
|
Oxygen consumption will be assessed with a mobile metabolic analyzer during walking on treadmill with 4 km/h gait speed.
Recordings will be taken for 2 minutes after first 2 minutes of walking.
|
Assessment will be done at the end of first month of conservative treatment.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pulmonary Functions
Time Frame: Assessment will be done at the end of first month of conservative treatment.
|
Forced vital capacity (FVC), Forced expiratory volume in one second (FEV1), FEV1/FVC ratio, peak expiratory flow (PEF), forced expiratory flow at 25-75 % of the pulmonary volume (FEF 25-75%) will be assessed with spirometer.
|
Assessment will be done at the end of first month of conservative treatment.
|
|
Balance
Time Frame: Assessment will be done at the end of first month of conservative treatment.
|
Balance will be assessed with a special equipment that gives deviation that lower values mean better.
|
Assessment will be done at the end of first month of conservative treatment.
|
|
Lower extremity loading symmetry
Time Frame: Assessment will be done at the end of first month of conservative treatment.
|
Plantar loading symmetry will be assessed with a pedobarograph located in the middle of a six meters walking way.
Loading symmetry will be calculated and compared as percentage of total pressure.
|
Assessment will be done at the end of first month of conservative treatment.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Yasin Yurt, Asst. Prof., Eastern Mediterranean University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ETK00-2016-0141
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.